Literature DB >> 26767390

Is treatment-resistant depression a useful concept?

Gin S Malhi1, Yulisha Byrow2.   

Abstract

The term treatment-resistant depression (TRD) is widely used in the context of managing mood disorders, but defining it, both conceptually and in practice, has proven difficult. Most definitions have focused on pharmacotherapy but even these have struggled to capture the complexity of varying response and duration of treatment. Both clinically and for research studies a meaningful definition of TRD is necessary because it may lead to the development of 'therapy-defined depressive subtypes' and the discovery of novel antidepressants. This brief perspective critically reviews the concept of treatment resistance and how it can be more clearly defined so as to achieve a better understanding of depression and facilitate clinical treatment trials. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26767390     DOI: 10.1136/eb-2015-102299

Source DB:  PubMed          Journal:  Evid Based Ment Health        ISSN: 1362-0347


  8 in total

1.  What is treatment resistance in psychiatry? A "difficult to treat" concept.

Authors:  Koen Demyttenaere
Journal:  World Psychiatry       Date:  2019-10       Impact factor: 49.548

2.  Is rTMS Ready for Primetime?

Authors:  Gin S Malhi; Erica Bell; Tim Outhred; Ajeet B Singh; Malcom Hopwood; Roger Mulder; Darryl Bassett; Zola Mannie
Journal:  Can J Psychiatry       Date:  2021-05-06       Impact factor: 4.356

3.  Ketamine: stimulating antidepressant treatment?

Authors:  Gin S Malhi; Yulisha Byrow; Frederick Cassidy; Andrea Cipriani; Koen Demyttenaere; Mark A Frye; Michael Gitlin; Sidney H Kennedy; Terence A Ketter; Raymond W Lam; Rupert McShane; Alex J Mitchell; Michael J Ostacher; Sakina J Rizvi; Michael E Thase; Mauricio Tohen
Journal:  BJPsych Open       Date:  2016-05-11

4.  Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression.

Authors:  Si-Tien Wang; Ian M Anderson; Dominic Mitchell; Scott J Johnson; Aki Shiozawa
Journal:  Clinicoecon Outcomes Res       Date:  2019-03-14

5.  Is cognitive dysfunction involved in difficult-to-treat depression? Characterizing resistance from a cognitive perspective.

Authors:  Clara López-Solà; Marta Subirà; Maria Serra-Blasco; Muriel Vicent-Gil; Guillem Navarra-Ventura; Eva Aguilar; Siddarta Acebillo; Diego J Palao; Narcís Cardoner
Journal:  Eur Psychiatry       Date:  2020-06-23       Impact factor: 5.361

6.  Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment.

Authors:  Yuri E Rybak; Ka S P Lai; Rajamannar Ramasubbu; Fidel Vila-Rodriguez; Daniel M Blumberger; Peter Chan; Nicholas Delva; Peter Giacobbe; Caroline Gosselin; Sidney H Kennedy; Hani Iskandar; Shane McInerney; Paula Ravitz; Verinder Sharma; Ari Zaretsky; Amer M Burhan
Journal:  Depress Anxiety       Date:  2021-02-02       Impact factor: 6.505

Review 7.  Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.

Authors:  Bashkim Kadriu; Laura Musazzi; Ioline D Henter; Morgan Graves; Maurizio Popoli; Carlos A Zarate
Journal:  Int J Neuropsychopharmacol       Date:  2019-02-01       Impact factor: 5.176

Review 8.  Glutamate and depression: Reflecting a deepening knowledge of the gut and brain effects of a ubiquitous molecule.

Authors:  Adejoke Yetunde Onaolapo; Olakunle James Onaolapo
Journal:  World J Psychiatry       Date:  2021-07-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.